Last reviewed · How we verify
BP1001 in combination with LDAC — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BP1001 in combination with LDAC (BP1001 in combination with LDAC) — Bio-Path Holdings, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BP1001 in combination with LDAC TARGET | BP1001 in combination with LDAC | Bio-Path Holdings, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BP1001 in combination with LDAC CI watch — RSS
- BP1001 in combination with LDAC CI watch — Atom
- BP1001 in combination with LDAC CI watch — JSON
- BP1001 in combination with LDAC alone — RSS
Cite this brief
Drug Landscape (2026). BP1001 in combination with LDAC — Competitive Intelligence Brief. https://druglandscape.com/ci/bp1001-in-combination-with-ldac. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab